CRESCENT BIOPHARMA, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 |
| Operating income | -$152.6M | -$40.0M | -$39.3M | -$47.4M |
| Operating expenses | $163.5M | $40.0M | $39.3M | $47.5M |
| Cash from operations | -$71.5M | -$31.1M | -$34.9M | -$46.5M |
| Capital expenditure | $919,000 | $9,972 | $21,394 | $84,191 |
| Free cash flow | -$72.5M | -$31.1M | -$34.9M | -$46.5M |
| Share repurchases | $177,000 | — | — | — |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M |
| Total liabilities | $37.3M | $47.1M | $6.9M | $8.9M |
Shares outstanding 27.6M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.